Completed
A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-week Treatment Switched to Tazorac® Cream, 0.1% 6-week Treatment in Patients With Acne Vulgaris
What is being tested
Adapalene Gel, 0.1%
+ Tazarotene Cream, 0.1%
+ Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Drug
Who is being recruted
Acne Vulgaris+2
+ Sebaceous Gland Diseases
+ Skin Diseases
From 12 to 35 Years
+3 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 4
Interventional
Study Start: February 2006
Summary
Principal SponsorGalderma R&D
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: February 1, 2006
Actual date on which the first participant was enrolled.Same as above.
Official TitleA Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-week Treatment Switched to Tazorac® Cream, 0.1% 6-week Treatment in Patients With Acne Vulgaris
Principal SponsorGalderma R&D
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
302 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 12 to 35 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Acne VulgarisSebaceous Gland DiseasesSkin DiseasesSkin and Connective Tissue DiseasesAcneiform Eruptions
Criteria
2 inclusion criteria required to participate
Subjects with a minimum of 20 inflammatory lesions (papules and pustules) on the face
Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open comedones and closed comedones) on the face, excluding the nose
1 exclusion criteria prevent from participating
Subjects with more than 3 nodulo-cystic lesions
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active ComparatorDifferin® Gel, 0.1% for 12 weeks
Group II
Active ComparatorTazorac® Cream, 0.1% for 12 weeks
Group III
Active ComparatorDifferin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 12 locations
Suspended
Therapeutics Clinical Research
San Diego, United StatesOpen Therapeutics Clinical Research in Google MapsSuspended
Henry Ford Medical Center-Dept. of Dermatology
Detroit, United StatesSuspended
Minnesota Clinical Study Center
Fridley, United StatesSuspended
State University of New York Downstate Medical Center-Dept. of Dermatology
Brooklyn, United StatesCompleted12 Study Centers